Virax Biolabs Presents at H.C. Wainwright's 26th Annual Global Investment Conference
Virax Biolabs (NASDAQ: VRAX), a biotechnology company specializing in viral disease detection and immune response diagnosis, announced its participation in H.C. Wainwright's 26th Annual Global Investment Conference in New York, NY. The company's Chief Operating Officer, Dr. Nigel McCracken, is presenting at the conference, which runs from September 9-11, 2024 at the Lotte New York Palace Hotel. A pre-recorded, on-demand presentation is now available for viewing.
Virax management is also offering one-on-one meetings during the conference for interested parties. The presentation can be accessed through the company's investor relations website.
Virax Biolabs (NASDAQ: VRAX), un'azienda biotecnologica specializzata nella rilevazione delle malattie virali e nella diagnosi della risposta immunitaria, ha annunciato la sua partecipazione al 26° Annual Global Investment Conference di H.C. Wainwright che si svolgerà a New York, NY. Il Direttore Operativo dell'azienda, Dr. Nigel McCracken, presenterà durante la conferenza, che si terrà dal 9 all'11 settembre 2024 presso il Lotte New York Palace Hotel. Una presentazione pre-registrata, disponibile on-demand, può già essere visionata.
La direzione di Virax offre anche incontri faccia a faccia durante la conferenza per le parti interessate. La presentazione è accessibile attraverso il sito web delle relazioni con gli investitori dell'azienda.
Virax Biolabs (NASDAQ: VRAX), una empresa biotecnológica especializada en la detección de enfermedades virales y el diagnóstico de la respuesta inmune, anunció su participación en la 26ª Conferencia Anual Global de Inversiones de H.C. Wainwright en Nueva York, NY. El Director de Operaciones de la empresa, Dr. Nigel McCracken, presentará en la conferencia, que se llevará a cabo del 9 al 11 de septiembre de 2024 en el Lotte New York Palace Hotel. Una presentación pregrabada, disponible bajo demanda, ya está disponible para su visualización.
La dirección de Virax también está ofreciendo reuniones individuales durante la conferencia para las partes interesadas. La presentación se puede acceder a través del sitio web de relaciones con inversores de la empresa.
Virax Biolabs (NASDAQ: VRAX)는 바이러스 질병 탐지 및 면역 반응 진단을 전문으로 하는 생명공학 회사로, 뉴욕 NY에서 열리는 H.C. Wainwright의 제26회 연례 글로벌 투자 컨퍼런스에 참여한다고 발표했습니다. 회사의 COO인 Dr. Nigel McCracken이 발표를 진행하며, 컨퍼런스는 2024년 9월 9일부터 11일까지 롯데 뉴욕 팰리스 호텔에서 개최됩니다. 사전 녹화된 온디맨드 발표가 현재 시청 가능합니다.
Virax 경영진은 관심 있는 당사자들과의 일대일 회의도 제공합니다. 발표는 회사의 투자자 관계 웹사이트를 통해 접근할 수 있습니다.
Virax Biolabs (NASDAQ: VRAX), une entreprise biotechnologique spécialisée dans la détection des maladies virales et le diagnostic de la réponse immunitaire, a annoncé sa participation à la 26ème Conférence Annuelle Globale d'Investissement de H.C. Wainwright à New York, NY. Le Directeur des Opérations de l'entreprise, Dr. Nigel McCracken, présentera lors de la conférence, qui se déroulera du 9 au 11 septembre 2024 au Lotte New York Palace Hotel. Une présentation préenregistrée, disponible à la demande, est maintenant accessible.
La direction de Virax propose également des réunions individuelles pendant la conférence pour les parties intéressées. La présentation est accessible via le site web des relations avec les investisseurs de l'entreprise.
Virax Biolabs (NASDAQ: VRAX), ein Biotechnologieunternehmen, das sich auf die Erkennung von Viruskrankheiten und die Diagnose der Immunantwort spezialisiert hat, hat seine Teilnahme an der 26. jährlichen Global Investment Conference von H.C. Wainwright in New York, NY, bekannt gegeben. Der Chief Operating Officer des Unternehmens, Dr. Nigel McCracken, wird während der Konferenz, die vom 9. bis 11. September 2024 im Lotte New York Palace Hotel stattfindet, präsentieren. Eine vorab aufgezeichnete, auf Abruf verfügbare Präsentation ist bereits verfügbar.
Das Management von Virax bietet auch Einzelgespräche während der Konferenz für interessierte Parteien an. Die Präsentation kann über die Investor-Relations-Website des Unternehmens aufgerufen werden.
- Participation in a major investment conference, potentially increasing visibility to investors
- Availability of management for one-on-one meetings, indicating openness to investor engagement
- None.
Session details are as follows:
Date: September 9-11, 2024 at Lotte New York Palace Hotel,
Title: Virax BioLabs Company Presentation
Virax Participant: Dr Nigel McCracken, Chief Operating Officer
Presentation Link: https://ir.viraxbiolabs.com
Virax management will be available during the conference for one-on-one meetings. Interested parties may request a one-on-one meeting.
About Virax Biolabs Group Limited
Virax Biolabs Group Limited is an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Virax Biolabs Group Limited is currently developing T-Cell-based test technologies with the intention of providing an immunology profiling platform. T-Cell testing can be particularly effective in the diagnosis and therapeutics of post-acute infection syndromes such as Long COVID and other chronic conditions linked to immune dysregulation.
For more information, please visit www.viraxbiolabs.com.
Investor Relations Contact:
Russo Partners, LLC
Nic Johnson and Adanna G. Alexander, Ph.D.
M: 303-482-6405
nic.johnson@russopartnersllc.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/virax-biolabs-presents-at-hc-wainwrights-26th-annual-global-investment-conference-302241974.html
SOURCE Virax Biolabs
FAQ
When is Virax Biolabs (VRAX) presenting at the H.C. Wainwright Global Investment Conference?
Who is representing Virax Biolabs (VRAX) at the H.C. Wainwright conference?
How can investors access Virax Biolabs' (VRAX) presentation from the H.C. Wainwright conference?
Is Virax Biolabs (VRAX) offering one-on-one meetings during the H.C. Wainwright conference?
